MedTrace Logo

A Phase I Dose Escalation Trial of PR104 Given Weekly in Subjects With Solid Tumors

NCT01358227 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2011-05-24

No results posted yet for this study

Summary

The purpose of this study is to determine the side effects and best weekly dose of PR104 in patients with advanced solid tumors.

Conditions

  • Unspecified Adult Solid Tumor, Protocol Specific

Interventions

DRUG

PR104

Dose escalation of PR104 to determine maximum tolerated dose for weekly administration

Sponsors & Collaborators

  • Proacta, Incorporated

    lead INDUSTRY

Principal Investigators

  • Mark McKeage, PhD, FRACP · University of Auckland, New Zealand

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-12-31
Primary Completion
2009-12-31
Completion
2010-01-31

Countries

  • New Zealand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01358227 on ClinicalTrials.gov